Switching drugs to the skin

To get to market faster, German dermatology play Switch Biotech AG is profiling drugs that have been approved in various indications and is reformulating them as topical treatments for skin diseases.

As a first example, Switch (Neuried, Germany) this month brought its SWT01.100 compound into Phase I trials to treat psoriasis. The small molecule ion channel modulator simultaneously acts on epidermal hyperproliferation and on immune cells by inhibiting both keratinocyte proliferation and T cell activation (see B10)...